Antitumor necrosis factor agents in crohn’s disease

Byron P. Vaughn

doi:10.1007/978-3-319-60276-9_3

Antitumor necrosis factor agents in crohn’s disease

Byron P. Vaughn

Medicine - Gastro, Hepatology, Nutrition Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Antitumor necrosis factor (anti-TNF) medications have revolutionized the treatment for Crohn’s disease (CD). The first anti-TNF was approved for CD in 1998, and since then a total of three anti-TNFs are approved by the FDA for use in CD: infliximab, adalimumab, and certolizumab pegol. This chapter will review each anti-TNF with regard to clinical efficacy (induction and maintenance of remission) as well as other key outcomes such as mucosal healing and fistula healing. Additionally this chapter will summarize key differences between the anti-TNFs and review why not all anti-TNFs work to treat CD. Anti-TNF medications have become the standard of care for moderate to severe CD. Understanding the evidence for the various anti-TNFs, as well as the pros and cons of each, is essential for practitioners treating patients with CD.

Original language	English (US)
Title of host publication	Treatment of Inflammatory Bowel Disease with Biologics
Publisher	Springer International Publishing
Pages	33-48
Number of pages	16
ISBN (Electronic)	9783319602769
ISBN (Print)	9783319602752
DOIs	https://doi.org/10.1007/978-3-319-60276-9_3
State	Published - Jan 1 2017

Keywords

Adalimumab
Antitumor necrosis factor
Certolizumab pegol
Crohn’s disease
Infliximab

Access

10.1007/978-3-319-60276-9_3

OpenUrl availability

Full text

Cite this

@inbook{5a85226849874e35a7e996e3ceb29156,

title = "Antitumor necrosis factor agents in crohn{\textquoteright}s disease",

abstract = "Antitumor necrosis factor (anti-TNF) medications have revolutionized the treatment for Crohn{\textquoteright}s disease (CD). The first anti-TNF was approved for CD in 1998, and since then a total of three anti-TNFs are approved by the FDA for use in CD: infliximab, adalimumab, and certolizumab pegol. This chapter will review each anti-TNF with regard to clinical efficacy (induction and maintenance of remission) as well as other key outcomes such as mucosal healing and fistula healing. Additionally this chapter will summarize key differences between the anti-TNFs and review why not all anti-TNFs work to treat CD. Anti-TNF medications have become the standard of care for moderate to severe CD. Understanding the evidence for the various anti-TNFs, as well as the pros and cons of each, is essential for practitioners treating patients with CD.",

keywords = "Adalimumab, Antitumor necrosis factor, Certolizumab pegol, Crohn{\textquoteright}s disease, Infliximab",

author = "Vaughn, {Byron P.}",

year = "2017",

month = jan,

day = "1",

doi = "10.1007/978-3-319-60276-9_3",

language = "English (US)",

isbn = "9783319602752",

pages = "33--48",

booktitle = "Treatment of Inflammatory Bowel Disease with Biologics",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Antitumor necrosis factor agents in crohn’s disease

AU - Vaughn, Byron P.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Antitumor necrosis factor (anti-TNF) medications have revolutionized the treatment for Crohn’s disease (CD). The first anti-TNF was approved for CD in 1998, and since then a total of three anti-TNFs are approved by the FDA for use in CD: infliximab, adalimumab, and certolizumab pegol. This chapter will review each anti-TNF with regard to clinical efficacy (induction and maintenance of remission) as well as other key outcomes such as mucosal healing and fistula healing. Additionally this chapter will summarize key differences between the anti-TNFs and review why not all anti-TNFs work to treat CD. Anti-TNF medications have become the standard of care for moderate to severe CD. Understanding the evidence for the various anti-TNFs, as well as the pros and cons of each, is essential for practitioners treating patients with CD.

AB - Antitumor necrosis factor (anti-TNF) medications have revolutionized the treatment for Crohn’s disease (CD). The first anti-TNF was approved for CD in 1998, and since then a total of three anti-TNFs are approved by the FDA for use in CD: infliximab, adalimumab, and certolizumab pegol. This chapter will review each anti-TNF with regard to clinical efficacy (induction and maintenance of remission) as well as other key outcomes such as mucosal healing and fistula healing. Additionally this chapter will summarize key differences between the anti-TNFs and review why not all anti-TNFs work to treat CD. Anti-TNF medications have become the standard of care for moderate to severe CD. Understanding the evidence for the various anti-TNFs, as well as the pros and cons of each, is essential for practitioners treating patients with CD.

KW - Adalimumab

KW - Antitumor necrosis factor

KW - Certolizumab pegol

KW - Crohn’s disease

KW - Infliximab

UR - http://www.scopus.com/inward/record.url?scp=85042263038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042263038&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-60276-9_3

DO - 10.1007/978-3-319-60276-9_3

M3 - Chapter

AN - SCOPUS:85042263038

SN - 9783319602752

SP - 33

EP - 48

BT - Treatment of Inflammatory Bowel Disease with Biologics

PB - Springer International Publishing

ER -

Antitumor necrosis factor agents in crohn’s disease

Abstract

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this